Nascent Biotech, Inc. (OTCMKTS:NBIO – Get Free Report)’s stock price passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $0.01 and traded as low as $0.0005. Nascent Biotech shares last traded at $0.0029, with a volume of 24,800 shares trading hands.
Nascent Biotech Price Performance
The firm has a 50 day moving average of $0.01.
Nascent Biotech Company Profile
Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.
See Also
- Five stocks we like better than Nascent Biotech
- How Can Investors Benefit From After-Hours Trading
- onsemi Places a $6 Billion Bet on Its Own Stock
- What Are Earnings Reports?
- HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?
- Upcoming IPO Stock Lockup Period, Explained
- End the Year Strong With These 3 Comeback Champions
Receive News & Ratings for Nascent Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nascent Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
-company-of-china-ltd-logo-1200x675.png?v=20240221105647&h=45&w=95&zc=2){kind=logo}
